TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06254469: Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encep

Sponsor: CereMark Pharma, LLC · Phase: PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 230 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$17,630,720

Rescue Site Savings

+$11,625,256

Unlock Full NCT06254469 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06254469 Rescue Dossier →